Farabegoli et al. showed EGCG’s ability to downregulate EGFR (epidermal growth factor receptor), MMP-2, MMP-9, and EMMPRIN (extracellular matrix metalloproteinase inducer), which is a glycoprotein able to activate MMPs in tamoxifen-resistant breast cancer cell line (MCF-7Tam). Here, EGFR is linked to breast carcinoma.